Shares of Immuron Rise as Reports No Impact From US Tariffs

MT Newswires Live

Oct 03

Shares of Immuron (ASX:IMC) rose past 8% in recent Friday trade after it said late Thursday that it expects no material impact from the newly introduced US tariffs on pharmaceutical products.

In the same statement, the company said top-line results from the clinical study of IMM-124E, or Travelan, for traveler's diarrhea will be released this month, advancing toward US Food and Drug Administration (FDA) phase 3 trials.

In addition, the company said it plans to submit an application with the US FDA by mid-October to advance IMM-529 into phase 2 trials for Clostridioides difficile infection, an infection of the colon caused by the Clostridioides difficile bacteria.

The company is fast-tracking a limited launch in Australia of ProIBS for irritable bowel syndrome in the fourth quarter, with a full rollout targeted for 2026. IMM-986, developed with Monash University, starts pre-clinical studies by year-end to tackle antimicrobial resistance, the company added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2572576704"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572576704\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572576704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 12:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572576704","market":"sg","top_or_hot":-1,"title":"Shares of Immuron Rise as Reports No Impact From US Tariffs","media":"MT Newswires Live","content":"<html><body><p> Shares of Immuron (ASX:IMC) rose past 8% in recent Friday trade after it said late Thursday that it expects no material impact from the newly introduced US tariffs on pharmaceutical products.</p><p>In the same statement, the company said top-line results from the clinical study of IMM-124E, or Travelan, for traveler's diarrhea will be released this month, advancing toward US Food and Drug Administration (FDA) phase 3 trials.</p><p>In addition, the company said it plans to submit an application with the US FDA by mid-October to advance IMM-529 into phase 2 trials for Clostridioides difficile infection, an infection of the colon caused by the Clostridioides difficile bacteria.</p><p>The company is fast-tracking a limited launch in Australia of ProIBS for irritable bowel syndrome in the fourth quarter, with a full rollout targeted for 2026. IMM-986, developed with Monash University, starts pre-clinical studies by year-end to tackle antimicrobial resistance, the company added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shares of Immuron Rise as Reports No Impact From US Tariffs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShares of Immuron Rise as Reports No Impact From US Tariffs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-03 12:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shares of Immuron (ASX:IMC) rose past 8% in recent Friday trade after it said late Thursday that it expects no material impact from the newly introduced US tariffs on pharmaceutical products.</p><p>In the same statement, the company said top-line results from the clinical study of IMM-124E, or Travelan, for traveler's diarrhea will be released this month, advancing toward US Food and Drug Administration (FDA) phase 3 trials.</p><p>In addition, the company said it plans to submit an application with the US FDA by mid-October to advance IMM-529 into phase 2 trials for Clostridioides difficile infection, an infection of the colon caused by the Clostridioides difficile bacteria.</p><p>The company is fast-tracking a limited launch in Australia of ProIBS for irritable bowel syndrome in the fourth quarter, with a full rollout targeted for 2026. IMM-986, developed with Monash University, starts pre-clinical studies by year-end to tackle antimicrobial resistance, the company added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2572576704","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572576704","pubTimestamp":1759466135,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shares of Immuron  rose past 8% in recent Friday trade after it said late Thursday that it expects no material impact from the newly introduced US tariffs on pharmaceutical products.In the same statement, the company said top-line results from the clinical study of IMM-124E, or Travelan, for traveler's diarrhea will be released this month, advancing toward US Food and Drug Administration  phase 3 trials.In addition, the company said it plans to submit an application with the US FDA by mid-October to advance IMM-529 into phase 2 trials for Clostridioides difficile infection, an infection of the colon caused by the Clostridioides difficile bacteria.The company is fast-tracking a limited launch in Australia of ProIBS for irritable bowel syndrome in the fourth quarter, with a full rollout targeted for 2026. IMM-986, developed with Monash University, starts pre-clinical studies by year-end to tackle antimicrobial resistance, the company added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","IMC.AU":"IMMURON LTD","BK7067":"生物科技"},"translate_title":"Immuron股价上涨，因为有报道称美国关税没有影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMC.AU":1},"content_text":"Shares of Immuron (ASX:IMC) rose past 8% in recent Friday trade after it said late Thursday that it expects no material impact from the newly introduced US tariffs on pharmaceutical products.In the same statement, the company said top-line results from the clinical study of IMM-124E, or Travelan, for traveler's diarrhea will be released this month, advancing toward US Food and Drug Administration (FDA) phase 3 trials.In addition, the company said it plans to submit an application with the US FDA by mid-October to advance IMM-529 into phase 2 trials for Clostridioides difficile infection, an infection of the colon caused by the Clostridioides difficile bacteria.The company is fast-tracking a limited launch in Australia of ProIBS for irritable bowel syndrome in the fourth quarter, with a full rollout targeted for 2026. IMM-986, developed with Monash University, starts pre-clinical studies by year-end to tackle antimicrobial resistance, the company added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}